A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer.

Abstract

Before the ABC-02 trial, because there was no standard chemotherapy for patients with advanced biliary tract cancer, we treated them with gemcitabine alone. However, recently cisplatin plus gemcitabine became the standard first-line chemotherapy. We assessed the benefits of gemcitabine plus cisplatin chemotherapy after failed gemcitabine monotherapy.